| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $299,773 ) |
| | 2024 | 2024 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AI172662 | Silencing autoantibody secretion for SLE therapy | 000 | 2 | NIH | 4/24/2024 | $299,773 |
| | 2024 | 2023 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AR083332 | Therapy for ectopic calcification in pseudoxanthoma elasticum | 000 | 1 | NIH | 10/18/2023 | $0 |
| | 2024 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 07 | 1 | CDC | 4/8/2024 | $0 |
| | 2024 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 07 | 1 | CDC | 4/8/2024 | $0 |
| | 2024 | 2021 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HL149492 | Novel therapy for myocardial ischemia-reperfusion injury | 000 | 1 | NIH | 1/29/2024 | $0 |
| | 2024 | 2021 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43CA261184 | Therapeutic antibody for cancer-associated cachexia | 000 | 1 | NIH | 1/11/2024 | $0 |
| | 2024 | 2021 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HL156695 | Inhibiting GPR146 in hypercholesterolemia | 000 | 1 | NIH | 12/29/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,127,282 ) |
| | 2023 | 2023 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AG085728 | Overcoming pressure ulcers with engineered hormones and stem cells | 000 | 1 | NIH | 9/15/2023 | $295,923 |
| | 2023 | 2023 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AI172662 | Silencing autoantibody secretion for SLE therapy | 000 | 1 | NIH | 5/8/2023 | $299,865 |
| | 2023 | 2023 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AR083332 | Therapy for ectopic calcification in pseudoxanthoma elasticum | 000 | 1 | NIH | 9/21/2023 | $285,766 |
| | 2023 | 2023 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HL154880 | Novel therapies for obesity- or diabetes-related lymphatic dysfunction | 000 | 1 | NIH | 8/24/2023 | $245,728 |
| | 2023 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HD107741 | Therapeutic antibody for hyperemesis gravidarum | 000 | 1 | NIH | 1/31/2023 | $0 |
| | 2023 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HD107741 | Therapeutic antibody for hyperemesis gravidarum | 001 | 1 | NIH | 2/2/2023 | $0 |
| | 2023 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AG080911 | Improved carnosic acid congener compounds for Alzheimer?s disease | 000 | 1 | NIH | 10/25/2022 | $0 |
| | 2023 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 05 | 1 | CDC | 1/20/2023 | $0 |
| | 2023 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 06 | 1 | CDC | 3/3/2023 | $0 |
| | 2023 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 04 | 1 | CDC | 10/7/2022 | $0 |
| | 2023 | 2021 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43CA261184 | Therapeutic antibody for cancer-associated cachexia | 000 | 1 | NIH | 11/1/2022 | $0 |
| | 2023 | 2020 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43DK126582 | Targeted Therapy for Type 1 diabetes | 000 | 1 | NIH | 6/2/2023 | $0 |
| | 2023 | 2020 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AR078684 | Targeted therapeutic for Netherton syndrome | 000 | 1 | NIH | 4/6/2023 | $0 |
| | 2023 | 2020 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HL150897 | Novel anti-fibrotic therapy for IPF | 000 | 1 | NIH | 7/13/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,523,971 ) |
| | 2022 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43MH130224 | Therapeutic antibody for anorexia nervosa | 000 | 1 | NIH | 2/22/2022 | $259,606 |
| | 2022 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HD107741 | Therapeutic antibody for hyperemesis gravidarum | 000 | 1 | NIH | 9/19/2022 | $300,847 |
| | 2022 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HD107719 | Advancing a novel therapy for preeclampsia | 000 | 1 | NIH | 9/1/2022 | $385,000 |
| | 2022 | 2022 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AG080911 | Improved carnosic acid congener compounds for Alzheimer?s disease | 000 | 1 | NIH | 9/24/2022 | $326,205 |
| | 2022 | 2022 | LARIX BIOSCIENCE LLC | 1230 Bordeaux Dr | Sunnyvale | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 03 | 1 | CDC | 9/9/2022 | $275,766 |
| | 2022 | 2022 | LARIX BIOSCIENCE LLC | 1230 Bordeaux Dr | Sunnyvale | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 00 | 1 | CDC | 8/10/2022 | $275,766 |
| | 2022 | 2022 | LARIX BIOSCIENCE LLC | 1230 Bordeaux Dr | Sunnyvale | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 01 | 1 | CDC | 8/30/2022 | $0 |
| | 2022 | 2022 | LARIX BIOSCIENCE LLC | 1230 Bordeaux Dr | Sunnyvale | CA | 94089-1202 | SANTA CLARA | USA | R43GH002390 | PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | 02 | 1 | CDC | 8/30/2022 | -$275,766 |
| | 2022 | 2021 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HL149492 | Novel therapy for myocardial ischemia-reperfusion injury | 000 | 1 | NIH | 8/4/2022 | $0 |
| | 2022 | 2019 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43CA243853 | Targeting TGF-beta activation in tumors | 000 | 1 | NIH | 3/14/2022 | -$21,729 |
| | 2022 | 2019 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43NS113704 | Dual Intracellular and Extracellular Expression Technology (dIEE) for Parkinson?s Disease | 000 | 1 | NIH | 3/16/2022 | $0 |
| | 2022 | 2018 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R44GM113478 | Human glyco-engineered CHO cells | 000 | 3 | NIH | 5/17/2022 | $0 |
| | 2022 | 2018 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43DK120065 | Targeting innate immunity in Type 1 diabetes | 000 | 1 | NIH | 2/16/2022 | $0 |
| | 2022 | 2018 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HD096943 | Novel GPCR-targeted therapy for preeclampsia | 000 | 1 | NIH | 2/22/2022 | $0 |
| | 2022 | 2018 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AG061983 | Dual Intracellular and Extracellular Expression Technology (dIEE) for Alzheimer????????????????????????s Disease | 000 | 1 | NIH | 2/24/2022 | -$1,723 |
|
| Issue Date FY: 2021 ( Subtotal = $754,016 ) |
| | 2021 | 2021 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43CA261184 | Therapeutic antibody for cancer-associated cachexia | 000 | 1 | NIH | 7/13/2021 | $252,282 |
| | 2021 | 2021 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HL149492 | Novel therapy for myocardial ischemia-reperfusion injury | 000 | 1 | NIH | 6/21/2021 | $252,000 |
| | 2021 | 2021 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HL156695 | Inhibiting GPR146 in hypercholesterolemia | 000 | 1 | NIH | 4/10/2021 | $249,734 |
| | 2021 | 2018 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R44GM113478 | Human glyco-engineered CHO cells | 000 | 3 | NIH | 1/26/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $718,459 ) (Continued on the next page) |
| | 2020 | 2020 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43HL150897 | Novel anti-fibrotic therapy for IPF | 000 | 1 | NIH | 5/28/2020 | $224,924 |
| | 2020 | 2020 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43AR078684 | Targeted therapeutic for Netherton syndrome | 000 | 1 | NIH | 9/3/2020 | $252,000 |
| | 2020 | 2020 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43DK126582 | Targeted Therapy for Type 1 diabetes | 001 | 1 | NIH | 9/18/2020 | $45,978 |
| | 2020 | 2020 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43DK126582 | Targeted Therapy for Type 1 diabetes | 001 | 1 | NIH | 9/18/2020 | -$45,978 |
| | 2020 | 2020 | LARIX BIOSCIENCE LLC | 1230 BORDEAUX DR | SUNNYVALE | CA | 94089-1202 | SANTA CLARA | USA | R43DK126582 | Targeted Therapy for Type 1 diabetes | 000 | 1 | NIH | 9/14/2020 | $250,000 |
|
